SHANGHAI, March 26, 2025 -- Shanghai Juncell Therapeutics Co., Ltd. (Juncell Therapeutics), a clinical-stage biotech developing innovative IL-2-independent Tumor-Infiltrating Lymphocyte (TIL) therapies for cancers, announced that a preclinical study of innovative pretreatment regimens for cell therapy will be presented at the American Association for Cancer Research (AACR) Annual Meeting, taking place April 25 - 30 in Chicago.

This study indicated that hydroxychloroquine (HCQ) could significantly increase the tumor-killing effects via elevating the membrane MHC-I protein levels of tumor cells without affecting TILs'proliferation. In addition, its effect on surface PD-L1 expression was not significant compared with IFN-γ. These results provide preclinical evidence for HCQ pretreatment of the adoptive cell therapy of TILs in clinical trials.

Details of the poster presentation are below:

Abstract Number: 5827
Abstract Title: Hydroxychloroquine increases the tumor killing efficiency via elevating the membrane MHC-I protein levels of tumor cells
Session Title: Immunomodulatory Agents and Interventions
Location: Poster Section 29
Poster Board Number: 3
Poster Presentation Time: 2:00 PM - 5:00 PM CST, April 29, 2025

About Juncell Therapeutics
Juncell Therapeutics is a biotech dedicated to developing high-quality, accessible TIL cell therapies for the treatment of solid tumors. Juncell Therapeutics has established its proprietary DeepTIL? cell expansion and NovaGMP? gene modification technology platforms, which are designed to address the key challenges of conventional TIL therapies, making TILs "robust, competent, affordable, and accessible." Two clinical-stage TIL therapies have demonstrated promising safety and efficacy in the treatment of ten types of heavily pretreated advanced solid tumors, including lung cancer, triple-negative breast cancer, pancreatic cancer, high-grade glioma, ovarian cancer, endometrial cancer, cervical cancer, head and neck cancer, bile duct cancer and melanoma. 7 of these late-stage tumor patients have achieved complete response, and the longest tumor-free survival time is over 3 years.

For more information, please visit:
https://www.linkedin.com/company/juncell-therapeutics 

Juncell Contact:
contact@juncell.com